Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Zentalis Pharmaceuticals has received a consensus recommendation of "Moderate Buy" from six research firms, with an average twelve-month target price of $8.37.
• Significant institutional investment increases were noted, such as Millennium Management LLC boosting its stake by 220.6% in the first quarter.
• The company's stock opened at $1.41 and has a market cap of $101.45 million, with analysts predicting earnings per share of -2.42 for the current fiscal year.

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $8.20.

A number of equities research analysts have recently weighed in on the stock. Wedbush restated a "neutral" rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a report on Thursday. Finally, Wells Fargo & Company lowered their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a report on Thursday.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Corton Capital Inc. bought a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $32,000. Captrust Financial Advisors bought a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $33,000. Prudential Financial Inc. bought a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $39,000. Cerity Partners LLC bought a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $40,000. Finally, Vident Advisory LLC bought a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $45,000.

Zentalis Pharmaceuticals Price Performance

ZNTL stock traded down $0.01 during midday trading on Wednesday, reaching $1.44. The company had a trading volume of 497,237 shares, compared to its average volume of 576,408. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $5.44. The company has a market capitalization of $103.61 million, a P/E ratio of -0.64 and a beta of 1.71. The firm has a 50-day moving average price of $1.37 and a 200-day moving average price of $1.56.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.19. On average, equities analysts predict that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.